AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00631371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg intravenous (IV) q8wks
Study NCT00631371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25 mg IV weekly
Study NCT00631371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg intravenous (IV) q8wks
Study NCT00631371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-Alfa 9MU
Description: Interferon-Alfa 9MU SC TIW
Study NCT03673007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)
Description: M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
Study NCT03673007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)
Description: M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
Study NCT00762892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir and truvada
Description: Raltegravir 400 mg po bid, truvada 1 tab q daily
Study NCT00762892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir, Norvir and Truvada
Description: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
Study NCT00916357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Study NCT01803386 — intervention group
Intervention type: DEVICE
Intervention: EIM Measurements
Description: EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
Study NCT00916357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R
Study NCT00916357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study NCT00935922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flaxseed
Description: Flaxseed omega-3 fatty acids and lignans
Study NCT03768648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
Study NCT03768648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ecological evaluation
Description: Virtual reality task : Urban DailyCog© and Actual reality
Study NCT03768648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological evaluation
Description: Virtual reality task : Urban DailyCog© and Actual reality
Study NCT03768648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Study NCT03768648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Study NCT01570504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: oral formulation
Study NCT01570504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: oral formulation
Study NCT03630328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cogni.Q
Description: AGN
Study NCT03630328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cogni.Q
Description: AGN
Study NCT03630328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03630328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00772954 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine diluent buffer
Description: 0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
Study NCT03768648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue
Study NCT03768648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue
Study NCT03768648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)
Study NCT03768648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)
Study NCT00772954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine (50 μg)
Description: 0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
Study NCT00772954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine (100 μg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
Study NCT04584580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-molecular-weight heparin
Description: low-molecular-weight heparin administered via subcutaneous injection
Study NCT04584580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-molecular-weight heparin
Description: low-molecular-weight heparin administered via subcutaneous injection
Study NCT01773109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (NKTR-102)
Description: Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
Study NCT02706821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Persimmon leaf extract
Description: Persimmon leaf extract (PLE), crossover design
Study NCT02706821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, crossover design
Study NCT03489382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone Assisted PST
Description: Emergency Departments randomized to the study intervention will receive:~1. Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~2. Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~3. The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men.
Study NCT00665457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00665457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00300196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ancrod (Viprinex)
Description: 0.167 IU/kg/hr IV for 2-3 hours
Study NCT00300196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.6 mL/kg/hr
Study NCT00665457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT00796419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% human albumin
Description: Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
Study NCT00796419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hetastarch
Description: Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
Study NCT00665457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT03290651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Natural Health Product - RepHresh Pro-B
Description: Participants will take the probiotic or placebo daily for 90 days.
Study NCT03290651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take the probiotic or placebo daily for 90 days.
Study NCT00665457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00665457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00665457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00691275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT03482596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing/breaking prolonged sitting
Description: The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour.
Study NCT00691275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02335281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT
Description: Standardized FMT once
Study NCT02335281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 2g Po perday
Study NCT00283335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemfibrozil
Study NCT02609490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan tablets
Description: 20mg/tablet
Study NCT02609490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan placebo tablets
Description: placebo tablet
Study NCT00283335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken once per day
Study NCT02609490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil tablets
Description: 20mg/tablet
Study NCT02609490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil placebo tablets
Description: placebo tablet
Study NCT02026141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02026141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Study NCT01870596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01870596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT01870596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHK1 Inhibitor SCH 900776
Description: Given IV
Study NCT02586558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Infant formula
Description: Ready-to-feed infant formula to be fed ad libitum
Study NCT01870596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01870596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02586558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference group
Description: Ready-to-feed infant formula to be fed ad libitum
Study NCT00665457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Study NCT00665457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00665457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT03160235 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study NCT03160235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Study NCT03160235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Study NCT00578734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant
Description: Slow intra-tracheal instillation
Study NCT00578734 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Slow intra-tracheal instillation
Study NCT00665457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging biomarker analysis
Study NCT02381691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maternal breast milk odor
Study NCT00665457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT02381691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no odor
Study NCT00665457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00665457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Study NCT01724268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pred + Meth
Description: PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
Study NCT01724268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti TNF + Meth
Study NCT04044508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketocal 4:1 liquid Nutricia (intervention)
Description: Modified ketogenic diet
Study NCT04044508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fortini multifibre Nutrica (placebo)
Description: Placebo diet
Study NCT00666770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
Study NCT00666770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
Study NCT00666770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime
Study NCT00900562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalypsis ( PM00104)
Description: Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
Study NCT01368328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium nicotinate
Description: The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
Study NCT01368328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chromium nicotinate
Description: The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
Study NCT02139592 — intervention group
Intervention type: DRUG
Intervention: Brentuximab vedotin (recombinant)
Description: Brentuximab vedotin (recombinant) for IV infusion
Study NCT03205449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)
Description: The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
Study NCT03205449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Effectiveness Service
Description: Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. \[12\].
Study NCT01856218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Study NCT01460043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathy
Description: Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
Study NCT01460043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
Study NCT00251043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for depression in pregnancy
Description: IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
Study NCT00251043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting education program (PEP)
Description: PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
Study NCT01121809 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: Changing the dose of raltegravir from 400 mg bid to 800 mg qd
Study NCT01121809 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etravirine
Description: Changing the dose of etravirine from 200 mg bid to 400 mg qd
Study NCT03180840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa
Description: Pegunigalsidase alfa 2 mg/kg every 4 weeks
Study NCT02648256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polymerase Chain Reaction on Oropharyngeal rinse
Study NCT04198051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months.
Study NCT03828071 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous hematopoietic stem cell transplantation
Description: Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \< 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition.
Study NCT01149148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS Somanetics Cerebral Oximeter
Description: Sequence of Interventions To Increase Cerebral Oxygen Saturation~1. Check head and cannula position~2. Increase mean arterial pressure~3. Increase pump flow~4. Increase systemic oxygenation~5. Increase PaCO2 > 45~6. Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~7. Consider PRBC transfusion for Hct \< 21%